Cyclacel Pharmaceuticals (NASDAQ:CYCC) Announces Earnings Results

Cyclacel Pharmaceuticals (NASDAQ:CYCC) announced its quarterly earnings data on Tuesday. The biotechnology company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.54) by $0.36, Zacks reports. The firm had revenue of $0.01 million during the quarter, compared to analysts’ expectations of $0.01 million. Cyclacel Pharmaceuticals had a negative net margin of 18,150.00% and a negative return on equity of 1,901.11%.

Cyclacel Pharmaceuticals Stock Down 6.6 %

Shares of NASDAQ:CYCC traded down $0.03 during trading on Wednesday, reaching $0.38. 11,918,183 shares of the company traded hands, compared to its average volume of 708,995. The firm has a fifty day simple moving average of $0.89 and a 200 day simple moving average of $1.45. Cyclacel Pharmaceuticals has a 1-year low of $0.37 and a 1-year high of $7.84. The firm has a market cap of $823,020.00, a P/E ratio of -0.05 and a beta of 0.56.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on CYCC. StockNews.com started coverage on shares of Cyclacel Pharmaceuticals in a research note on Thursday, November 7th. They set a “sell” rating for the company. Roth Capital downgraded shares of Cyclacel Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 23rd.

Cyclacel Pharmaceuticals Company Profile

Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies.